Ekso Bionics Files Q1 2025 10-Q
Ticker: EKSO · Form: 10-Q · Filed: May 5, 2025 · CIK: 1549084
| Field | Detail |
|---|---|
| Company | Ekso Bionics Holdings, Inc. (EKSO) |
| Form Type | 10-Q |
| Filed Date | May 5, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, equity
TL;DR
Ekso Bionics Q1 2025 10-Q is in. Check financials for latest burn rate.
AI Summary
Ekso Bionics Holdings, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates. Key figures include revenue, net loss, and cash flow, which are crucial for understanding the company's financial health and future prospects.
Why It Matters
This filing provides investors and analysts with the latest financial data for Ekso Bionics, impacting investment decisions and market perception of the company's exoskeleton technology.
Risk Assessment
Risk Level: medium — The company operates in a specialized, capital-intensive industry with significant research and development costs, making it susceptible to market adoption and funding challenges.
Key Numbers
- 141,429 — Total Assets (As of March 31, 2025)
- 28,197 — Total Liabilities (As of March 31, 2025)
- 22,203 — Total Equity (As of March 31, 2025)
Key Players & Entities
- EKSO BIONICS HOLDINGS, INC. (company) — Filer
- 20250331 (date) — Period of Report
- 20250505 (date) — Filed as of Date
- PN Med Group Inc (company) — Former Company Name
- 20120503 (date) — Date of Name Change
FAQ
What was Ekso Bionics' net loss for the quarter ended March 31, 2025?
The filing indicates a net loss, but the specific dollar amount for the quarter is not explicitly stated in the provided snippet. Further review of the full 10-Q is needed.
What is the company's primary business activity?
Ekso Bionics Holdings, Inc. is involved in the development and manufacturing of exoskeleton technology, as indicated by its SIC code for General Industrial Machinery & Equipment.
Where is Ekso Bionics Holdings, Inc. headquartered?
The company is headquartered in San Rafael, California, with a business address at 101 Glacier Point, Suite A, San Rafael, CA 94901.
What is the significance of Note 11 mentioned in the filing?
Note 11 pertains to Capitalization and Equity Structure, specifically detailing information regarding Stockholder Dividends and the valuation of warrants, including the Inducement Warrant.
When was the company formerly known as PN Med Group Inc?
The company changed its name from PN Med Group Inc on May 3, 2012.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 5, 2025 regarding EKSO BIONICS HOLDINGS, INC. (EKSO).